AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis

After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. This time, the AbbVie and Boehringer Ingelheim-partnered biologic has gone head-to-head against Amgen’s Otezla.